Brief: Transcode Therapeutics Announces Orphan Drug Designation Status For Ttx-Mc138 For Treatment Of Pancreatic Cancer
28/02/2023 14:33
Feb 28 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS ANNOUNCES ORPHAN DRUG DESIGNATION
STATUS
FOR TTX-MC138 FOR TREATMENT OF PANCREATIC CANCER
Source text for Eikon: ID:nGNXxPJDR
Further company coverage: RNAZ.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors